Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Recruiting · NCT07017673 · Registry updated 2026-08-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-08-04 | NCT07017673 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cedars-Sinai Medical Center | 161 |
| Summit Therapeutics | 31 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| Cedars-Sinai Medical Center Beverly Hills | Los Angeles | United States | 2 |
| Hunt Cancer Institute, an Affiliate of CS Cancer | Torrance | United States | 2 |
| Huntington Cancer Center, an Affiliate of CS Cancer | Pasadena | United States | 1 |